Current State of ERG as Biomarker in Prostatic Adenocarcinoma.

Current State of ERG as Biomarker in Prostatic Adenocarcinoma.
Curr Cancer Drug Targets. 2015;15(8):643-51
Authors: Acs B, Szarvas T, Szekely N, Nyirady P, Szasz AM
Abstract
In this review we briefly discuss the possible biomarkers of prostate cancer among them we focus and analyze the relevance of TMPRSS2-ERG fusion gene in line with ERG expression in the diagnosis of prostate cancer. Starting at diagnosis and genetic alterations in prostate carcinomas, we examine the incidence and detection of the most common genetic aberration in this tumor and its protein product as well. We also examined the correlation of clinicopathological factors and prognosis with ERG and the TMPRSS2-ERG fusion oncogene and ERG expression as predictive markers.
PMID: 26452381 [PubMed - in process]

Source: Current Cancer Drug Targets - October 12, 2015 Category: Cancer & Oncology Authors: Acs B, Szarvas T, Szekely N, Nyirady P, Szasz AM Tags: Curr Cancer Drug Targets Source Type: research